Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities.
about
Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta poresAlzheimer's Disease: Mechanism and Approach to Cell TherapyInteractions between inflammation, sex steroids, and Alzheimer's disease risk factorsExercise, APOE genotype, and the evolution of the human lifespanThe influence of HLA on HIV-associated neurocognitive impairment in Anhui, ChinaGenetic determinants of target and novelty-related event-related potentials in the auditory oddball response.Pharmaceutical induction of ApoE secretion by multipotent mesenchymal stromal cells (MSCs).Molecular basis for increased risk for late-onset Alzheimer disease due to the naturally occurring L28P mutation in apolipoprotein E4.Relationship between mastication and cognitive function in elderly in L'Aquila.The genetics of white matter lesions.Genetic connections between neurological disorders and cholesterol metabolismSex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline.APOE epsilon4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors.CNF1 increases brain energy level, counteracts neuroinflammatory markers and rescues cognitive deficits in a murine model of Alzheimer's disease.Alterations in brain leptin signalling in spite of unchanged CSF leptin levels in Alzheimer's disease.Vitamin D receptor and megalin gene polymorphisms and their associations with longitudinal cognitive change in US adultsAP-2β regulates amyloid beta-protein stimulation of apolipoprotein E transcription in astrocytes.Enhanced Diabetes Susceptibility in Community Dwelling Han Elders Carrying the Apolipoprotein E 3/3 GenotypeAn apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines.Innovative Research Design Exploring the Effects of Physical Activity and Genetics on Cognitive Performance in Community-Based Older Adults.Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype.Genetics as a molecular window into recovery, its treatment, and stress responses after strokeBiomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?Gene therapy in Alzheimer's disease - potential for disease modificationDietary deficiency increases presenilin expression, gamma-secretase activity, and Abeta levels: potentiation by ApoE genotype and alleviation by S-adenosyl methionine.APOE and ACE polymorphisms and dementia risk in the older population over prolonged follow-up: 10 years of incidence in the MRC CFA Study.Chaperone signalling complexes in Alzheimer's disease.Brain plasticity and genetic factors.Apolipoprotein E4 Elicits Lysosomal Cathepsin D Release, Decreased Thioredoxin-1 Levels, and Apoptosis.What have the genomics ever done for the psychoses?Intracellular calcium signalling in Alzheimer's diseasePlasma cholesterol and risk for late-onset Alzheimer's disease.Review: cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy.Pathways to Alzheimer's disease.Interconnection between brain and retinal neurodegenerations.Vitamin D Receptor and Megalin Gene Polymorphisms Are Associated with Longitudinal Cognitive Change among African-American Urban Adults.Oxidative Stress Induced Mitochondrial Failure and Vascular Hypoperfusion as a Key Initiator for the Development of Alzheimer Disease.Age of onset of mesial temporal lobe epilepsy with hippocampal sclerosis: the effect of apolipoprotein E and febrile seizures.Cardiovascular dementia - a different perspective.Alzheimer's disease: diagnostics, prognostics and the road to prevention.
P2860
Q26738355-0693AC6C-7D94-48C4-887E-04F4509B751CQ26778149-E3ACE31E-E074-4B2B-8B5C-4B54FDF31847Q28394967-AA0781C7-58FE-4DBD-96E1-4D70C30B1968Q28657798-D7609411-EFF4-4A70-949B-8DBF226DA177Q28729004-DE364ADF-3D45-4F94-AE15-435CC99FA666Q30480819-0C08E4F5-48EF-4BED-9C58-EA2F1D4932F9Q33372606-424037EC-8757-44C3-92C8-1313E45E4467Q33556316-A44C5EE5-4448-4096-8989-D27A1A5A7328Q33756318-A8FABABC-9AE8-4F9D-9DA6-0DD6DE8DA836Q34032512-71507683-DD14-41D7-9769-E91DAB398BC1Q34053056-15E26B0C-DED7-4F31-87EC-A611329544D1Q34284146-BE21EA2A-4A3D-4CFD-99F1-F34AD748CC09Q34714286-9A4E96D2-E31A-4FB6-93C8-61501C3C34F3Q34759070-AC254981-0D43-436C-8ECD-19DA791B59B0Q35080530-92299315-5F41-4C78-87D8-90FEE9435CD0Q35615257-5A265F09-9057-40D0-A2F6-45705776CE26Q35798851-921E1ED7-FE0F-4D50-B022-BAFBAA369B0AQ35964648-21398812-FA3A-482D-A67F-919F2E6656A8Q35981432-BD824B72-CFFD-4507-8270-47ED425EDB71Q36105395-F0EF09AF-FE10-40A8-BA06-241967B96F61Q36457368-C5A0D311-6DCB-4E08-BA53-2CA36CF8161FQ37088174-B7BC0F20-6676-4F99-B78B-D97F80095555Q37118083-4F07EA89-1E6D-4651-AE36-29BEBA245DE1Q37295252-74347E03-4C25-4386-A47F-2871D268010EQ37398555-0730BF4A-FBB1-4235-BF0C-8E9732C2263EQ37478242-E314CC11-45D4-424B-AB49-2FDADB229FC7Q37486421-5A3CF9D2-B690-402F-B3D4-CACD89D0A198Q37594329-38275416-7E39-4ADA-8893-7A08206672B6Q37610551-2798D5F3-60B3-4D62-A05B-0D2E0DF2CE8CQ37612075-89CC0905-7E96-4BC7-BD82-89A36ED5254DQ37636324-E22D7AFA-8420-4CE1-9891-FB98CFDD45EBQ37862233-4F85EDF9-1FA1-48DC-A87D-80A9DCB088E6Q38089232-A4A5AFB6-67F3-4B00-8A01-F69D35B8A84EQ38205782-796BAC0E-C072-4F41-9BEF-0837D8553830Q38211671-F4D72594-DC38-48DD-942B-490C577A2405Q38818022-996E2776-3CD9-4314-8F76-CD2342CDF069Q38818702-B3C330B0-21A2-432C-85DB-A738C2EAB376Q39162843-F5C6F143-A4EF-4BEE-8BDE-65D4B9D3914AQ40361355-A1C99CAF-B082-4BEE-BC3C-321BCD668A75Q41731898-069C353C-FFA4-41CC-8746-150E8A97F6B3
P2860
Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Apolipoprotein E and Alzheimer ...... and therapeutic opportunities.
@en
Apolipoprotein E and Alzheimer ...... and therapeutic opportunities.
@nl
type
label
Apolipoprotein E and Alzheimer ...... and therapeutic opportunities.
@en
Apolipoprotein E and Alzheimer ...... and therapeutic opportunities.
@nl
prefLabel
Apolipoprotein E and Alzheimer ...... and therapeutic opportunities.
@en
Apolipoprotein E and Alzheimer ...... and therapeutic opportunities.
@nl
P2860
P921
P1476
Apolipoprotein E and Alzheimer ...... and therapeutic opportunities
@en
P2093
Angel Cedazo-Mínguez
P2860
P304
P356
10.1111/J.1582-4934.2007.00130.X
P577
2007-11-01T00:00:00Z